Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

pany had $52 million of long-term marketable securities at March 31, 2008.

EBITDA

Earnings before interest, taxes, depreciation and amortization (EBITDA) for the first quarter of 2008 totaled $153 million, compared to $158 million in the prior year period. Please see the EBITDA reconciliation table at the end of this press release.

Sanctura(R) Payment from Allergan, Inc.

On May 5, 2008, the Company entered into an agreement with a subsidiary of Allergan, Inc. related to Allergan's Sanctura(R) product that PLIVA divested in 2005 to Esprit Pharma, which has since been acquired by Allergan. Under the terms of this agreement, Allergan paid Barr $53 million, extinguishing any future payment obligations related to Sanctura(R). Barr will record the $53 million in the Company's second quarter 2008 earnings.

Revised 2008 Financial Outlook

The Company is revising its adjusted earnings per fully diluted share guidance for 2008 to be in the range of approximately $2.75 - $3.05, down from the $3.05 -$3.35 range that the Company provided in February 2008. The decrease in the range is the result of several factors, including the Company's results for the first quarter of 2008, which were lower than it expected, lower than anticipated U.S. generic revenues due to timing of new product launches, lower than anticipated Plan B revenues, lower gross profit margins due to a shift in product mix, and increased investment in R&D. The impact of these factors will not be fully offset by contributions from the Company's expected launch of generic Yasmin (drospirenone and ethinyl estradiol) in mid-2008. The Company's adjusted earnings guidance excludes the $53 million one-time payment from Allergan related to the Sanctura product.

Based on the factors listed above, the Company expects total revenues for 2008 to be in the range of $2.7 - $2.8 billion, including total product sales in the range of $2.5 - $2.6 billion. Revenue and product sales es
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company update ... took place on Tuesday, June 16 and provided an update on the achievement of ... of pancreatic cancer. A copy of the company overview can be found on ...
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... Falls Church, VA (PRWEB) , ... June 30, ... ... technology, and strategy services to the federal government, announced in a paper published ... Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... CRANBURY, N.J., Sept. 24 Palatin Technologies, Inc. (NYSE ... of its workforce and operations to reflect a strategic ... objectives. As a result, Palatin will focus resources and ... female sexual dysfunction and PL-3994 for acute severe asthma. ...
... 24, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Cylene Pharmaceuticals, Inc. announced today the initiation ... first-in-class, oral CK2 inhibitor CX-4945 in patients with ... of a $12 million financing with participation from ... Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, ...
Cached Biology Technology:Palatin Announces Strategic Realignment of Operations 2Palatin Announces Strategic Realignment of Operations 3Palatin Announces Strategic Realignment of Operations 4Palatin Announces Strategic Realignment of Operations 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 2Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 3Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 4Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 6Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 7Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... by wood-eating gribble that destroyed their ships, and these ... docks in coastal communities. , But new research ... the Universities of York and Portsmouth is uncovering how ... , By examining genes that are expressed in the ...
... ITHACA, N.Y. - Another weapon in the arsenal ... cancer cells while leaving healthy cells alone. Led ... Food Science, the researchers synthesized nanoparticles shaped something ... two pieces of iron oxide. They then attached antibodies, ...
... BINGHAMTON, NY -- In his recent book, "Strategic Bargaining ... Yang suggests ways governments might realistically work together to ... for curbing the use of fossil fuels whether ... global warming is factually true and I,m not ...
Cached Biology News:Seafarers' scourge provides hope for biofuel future 2Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Cool model for a hot planet 2Cool model for a hot planet 3